TScan Therapeutics (TCRX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TCRX TScan Therapeutics

Watchlist

2.910
-0.100-3.32%

Close Dec 24 13:00 ET

2.910
0.0000.00%

Post 14:30 ET

155.31MMarket Cap-3.06P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

With 52% Ownership, TScan Therapeutics, Inc. (NASDAQ:TCRX) Boasts of Strong Institutional Backing
Yahoo FinanceDec 25 05:26 ET
Express News | TScan Therapeutics Inc - Refinancing Expected to Fund Operating Plan Into Q4 2026
ReutersDec 23 07:04 ET
Express News | TScan Therapeutics Inc - Term Loans Mature on September 1, 2029
ReutersDec 23 07:04 ET
Express News | TScan Therapeutics Refinances Existing Convertible Debt Facility With Term Loan for up to $52.5 Million From Silicon Valley Bank
ReutersDec 23 07:00 ET
Press Release: TScan Therapeutics Refinances Existing Convertible Debt Facility With Term Loan for up to $52.5 Million From Silicon Valley Bank
Dow JonesDec 23 07:00 ET
Insider Purchase: 10% Owner at $TCRX (TCRX) Buys 31,800 Shares
Quiver QuantitativeDec 16 16:32 ET

Comments

Trytosaveabit

Dec 9 16:55

Watching

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting
Benzinga· 1 min ago
TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.
The company said it is high...

MARKET-TEST-DUMMY

Dec 7 05:06

👁

$TScan Therapeutics (TCRX.US)$

Jaguar8

Nov 5 08:16

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Jaguar8

Oct 4 10:40

NEWS

$TScan Therapeutics (TCRX.US)$
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentationat the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houst...

Trytosaveabit

May 29 06:08

News

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
Benzinga· 2 mins ago

Heat List

Overall

No Data